Research conducted at the University of Texas has identified an important role of psychological disorders in the early readmission of patients with chronic obstructive pulmonary disease.
Research conducted at the University of Texas has identified an important role of psychological disorders in the early readmission of patients with chronic obstructive pulmonary disease (COPD).
COPD is estimated to affect 12 to 24 million individuals and is one of the leading causes of death in the United States. One in five patients with the condition need readmission within 30 days of their primary admission, which can be a huge burden on hospitals especially with the fines levied by CMS on this front.
The authors of the study, published in the journal Chest, analyzed data from fee-for-service Medicare beneficiaries with COPD over a 10-year period between 2001 and 2011 who were hospitalized with a primary discharge diagnosis of COPD or primary discharge diagnosis of respiratory failure with secondary diagnosis of COPD. The study hypothesis was that psychological disorders (depression, anxiety, psychosis, alcohol abuse, and drug abuse) are independently associated with an increased risk of 30-day readmission in patients with COPD.
During their study period, the authors documented 135,498 hospitalizations for COPD in over 80,000 fee-for-service Medicare enrollees. About 22% of these patients had 1 or more psychological disorders, and multivariate analysis identified 5% to 14% higher 30-day readmissions in these individuals compared with those who did not have these disorders. These patients also had a longer initial length of time in the hospital and a lower rate of outpatient follow-up visits within the first month after discharge.
According to study author Gurinder Singh, "These psychological disorders are more likely to predict early readmission than other significant factors. This is likely related to the limited ability of these patients to handle the COPD, poor social support or community resources and non-adherence with treatment. Because of the complexity of this situation, hospitals and healthcare providers need more guidance to reduce readmission in patients with COPD, and it may not be practical to penalize hospitals for higher early readmission rates. More studies are needed in this area."
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More